TY - JOUR
T1 - Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation
AU - Fahey, John L.
AU - Aziz, Najib
AU - Spritzler, John
AU - Plaeger, Susan
AU - Nishanian, Parunag
AU - Lathey, Janet L.
AU - Seigel, Joan
AU - Landay, Alan L.
AU - Kilarui, Rakhi
AU - Schmitz, John L.
AU - White, Carmen
AU - Wara, Diane W.
AU - Akridge, Robert
AU - Cutili, Joie
AU - Douglas, Steven D.
AU - Reuben, James
AU - Shearer, William T.
AU - Nokta, Mustafa
AU - Polland, Richard
AU - Schooley, Robert
AU - Asthana, Deshratn
AU - Mizrachi, Yaffa
AU - Waxdal, Myron
PY - 2000/7
Y1 - 2000/7
N2 - An external evaluation program for measuring the performance of laboratories testing for cytokines and immune activation markers in biological fluids was developed. Cytokines, chemokines, soluble cytokine receptors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, Rantes, MIP-Ia, MIP-Iβ, soluble TNF receptor II, soluble IL-2 receptor alpha, β2-microglobulin, and neopterin. Twelve laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The performance features that were evaluated included intralaboratory variability, interlaboratory variability, comparison of reagent sources, and ability to detect CSM in the plasma of normal subjects as well as the changes occurring in disease. The principal findings were as follows: (i) on initial testing, i.e., before participating in the program, laboratories frequently differed markedly in their analytic results; (ii) the quality of testing of a CSM in individual participating laboratories could be assessed; (iii) most commercial kits allowed distinction between normal and abnormal plasma CSM levels and between supernatants of stimulated and unstimulated cells; (iv) different sources of reagents and reference standards frequently provided different absolute values; (v) inexperienced laboratories can benefit from participating in the program; (vi) laboratory performance improved during active participation in the program; and (vii) comparability between analyses conducted at different sites can be ensured by an external proficiency testing program.
AB - An external evaluation program for measuring the performance of laboratories testing for cytokines and immune activation markers in biological fluids was developed. Cytokines, chemokines, soluble cytokine receptors, and other soluble markers of immune activation (CSM) were measured in plasma from a healthy human immunodeficiency virus (HIV)-seronegative reference population and from HIV-seropositive individuals as well as in supernatant fluids from in vitro-stimulated human immune cells. The 14 components measured were tumor necrosis factor (TNF) alpha, gamma interferon, interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-10, Rantes, MIP-Ia, MIP-Iβ, soluble TNF receptor II, soluble IL-2 receptor alpha, β2-microglobulin, and neopterin. Twelve laboratories associated with the Adult and Pediatric AIDS Clinical Trial Groups participated in the study. The performance features that were evaluated included intralaboratory variability, interlaboratory variability, comparison of reagent sources, and ability to detect CSM in the plasma of normal subjects as well as the changes occurring in disease. The principal findings were as follows: (i) on initial testing, i.e., before participating in the program, laboratories frequently differed markedly in their analytic results; (ii) the quality of testing of a CSM in individual participating laboratories could be assessed; (iii) most commercial kits allowed distinction between normal and abnormal plasma CSM levels and between supernatants of stimulated and unstimulated cells; (iv) different sources of reagents and reference standards frequently provided different absolute values; (v) inexperienced laboratories can benefit from participating in the program; (vi) laboratory performance improved during active participation in the program; and (vii) comparability between analyses conducted at different sites can be ensured by an external proficiency testing program.
UR - http://www.scopus.com/inward/record.url?scp=0033942070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033942070&partnerID=8YFLogxK
U2 - 10.1128/CDLI.7.4.540-548.2000
DO - 10.1128/CDLI.7.4.540-548.2000
M3 - Article
C2 - 10882648
AN - SCOPUS:0033942070
SN - 1071-412X
VL - 7
SP - 540
EP - 548
JO - Clinical and Diagnostic Laboratory Immunology
JF - Clinical and Diagnostic Laboratory Immunology
IS - 4
ER -